5-Fluorouracil pharmacogenetics

Hitre E, Budai B, Adleff V et al. Influenee of thymidylate synthase gene polymorphisms on the survival of eoloreetal eaneer patients reeeiving adjuvant 5-fluorouracil. Pharmacogenet Genomics... [Pg.171]

Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacoge-nomics in cancer chemotherapy with 5-fluorouracil. Pharmacology 2000 61 199-203. [Pg.305]

Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991 68(3) 499-501. [Pg.1419]

Goekkurt E, Al-Batran SE, Hartmann JT et al (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27 2863-2873... [Pg.320]

Pare L, Marcuello E, Altes A et al (2008) Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99 1050-1055... [Pg.321]

Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 2002 12(7) 555-8. [Pg.28]

Lee A, Ezzeldin H, Fourie J, et al. Dihydropyrimidine dehydrogenase deficiency impact of pharmacogenetics on 5-fluorouracil therapy. Clin Adv Hematol Oncol 2004 2 527-532. [Pg.1844]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...